J&J’s Red River Talc unit made its filing in the U.S. Bankruptcy Court for the Southern District of Texas. J&J faces lawsuits from more than 62,000 claimants who alleged that its baby powder ...

J&J has won most of the trials in ovarian cancer cases and it successfully appealed some of its initial losses, with a $2 billion verdict standing as an outlier loss for the company.

J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...

Per terms of the offer, there is an upper limit of 8.0549 shares of Kenvue common stock per share of J&J. If that upper limit is not in effect, J&J shareholders can expect to receive $107.53 of Kenvue ...

Pharmaceutical company claims Cigna units worked with SaveOn and caused J&J to pay more than $100 million in copay assistance than it would have otherwise. Skip to Main Content.

J&J’s business development strategy for the new year follows a record-setting 2023 for R&D allocation, with $15.1 billion spent— representing 17.7% percent of sales.

J&J said the disease control and survival data compare favorably to historical data in heavily pretreated mCRPC patients. The authors of the ASCO abstract said phase 3 trials are planned.